Flu season is back.
And, as any one with a respiratory system will tell you, this time of year isn’t always fun... unless, of course, you’re an investors in flu-related, coughing, sniffling, remedy stocks that typically take off around this time of year.
Clorox (CLX), for example, has an historical tendency to appreciate every flu season, as do pharmacy-related stocks, like Rite Aid (RAD) and CVS Health (CVS).
Then, there’s ProPhase Labs. Inc. (PRPH), the maker of Cold-EEZE products, which has a tendency to move higher in the colder, winter months of the year. The Cheap Investor has recommended the stock twice in 2011 at 87 cents and $1.00. It last traded at $2.14.
Earnings have been a recent driver. In fact, for the three months ended June 30, 2016, the company posted net sales of $2.8 million, as compared to $2.2 million year over year. Its net loss for the quarter was six cents, as compared to a year-earlier loss of 10 cents.
While we’re not recommending a new buy on any of the above-mentioned names, we did want to bring the story back to your attention, as we try to do each flu season.